Abstract
The adenosine analogue 5,6-dichloro-1-.beta.-D-ribofuranosylbenzimidazole (DRB) is a specific inhibitor for RNA polymerase II transcription in vivo and in vitro [Tamm and Sehgal (1978) Adv. Virus Res. 22, 187-258; Zandomeni and Weinmann (1984) J. Biol. Chem. 259, 14804-14811]. The effect on RNA polymerase II-specific transcription seems to be mediated by its inhibition of nuclear casein kinase II [Zandomeni, Carrera-Zandomeni, Shugar and Weinmann (1986) J. Biol. Chem. 261, 3414-3419]. Inhibition studies indicated that DRB acted as a mixed-type inhibitor with respect to casein and as a competitive inhibitor with respect to the nucleotide phosphate donor substrates. The DRB inhibition constant is 7 .mu.m for the calf thymus casein kinase II, with regard to both ATP and GTP.

This publication has 25 references indexed in Scilit: